Ice Cream Recalled Nationwide As Warning Issued Over Products
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Tropicale Foods, based in Ontario, California, announced on Friday a voluntary recall of select Helados Mexico and La Michoacana ice cream products.
The decision followed a label audit which revealed that although the products list "cream," they do not explicitly declare "milk"—that could endanger those allergic to milk.
Newsweek contacted the company for comment on Sunday via email outside of usual working hours.
Why It Matters
Milk is a major allergen under federal labeling laws, and its accidental presence in products poses a risk to consumers with allergies or severe sensitivities.
Undeclared ingredients can trigger life-threatening reactions, making accurate labeling a critical public health requirement.
A gelato store at the Caesars Forum Shops is viewed on May 29, 2025 in Las Vegas, Nevada.
A gelato store at the Caesars Forum Shops is viewed on May 29, 2025 in Las Vegas, Nevada.What to Know
The company announcement, published on the Food and Drug Administration (FDA)'s website on Saturday, states: "Tropicale Foods of Ontario, CA is recalling certain Helados Mexico and La Michoacana products with specific best by dates, as detailed below because these products contain undeclared milk.
"Though these products include 'cream' in the product ingredient lists, the common name 'milk' is not declared. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products."
Affected items include single-flavor offerings (such as Coconut, Strawberry, Bubble Gum, Cookies and Cream, Mango), as well as multi-packs (6‑pack, 12‑pack, 16‑pack varieties). The recalled products are as follows:
Description BBD LaMichoacana COCONUT (Single) 10/3/2026-5/3/2027 LaMichoacana STRAWBERRY (Single) 10/1/2026-5/16/2027 LaMichoacana BUBBLE GUM (Single) 4/7/2027-4/19/2027 LaMichoacana COOKIES AND CREAM (Single) 4/9/2027-4/11/2027 LaMichoacana MANGO (Single) 2/3/2027-4/8/2027 LaMichoacana 6 -PACK COCONUT 11/25/2026-4/12/2027 LaMichoacana 6-PACK STRAWBERRY 6/3/2026-6/17/2027 LaMichoacana 16-PACK VARIETY CREAM 3/14/2027 and 3/16/2027 LaMichoacana 12-PACK MINI VARIETY CREAM 9/9/2026 -4/12/2027 LaMichoacana 6-PACK ROMPOPE 4/24/2027-7/14/2027 Helados Mexico 12-PACK MINI VARIETY CREAM 5/29/2026-06/24/2027 Helados Mexico 12-PACK MINI CHOCOLATEDIP VARIETY CREAM 12/17/2026-6/15/2027 Helados Mexico 12-PACK DLR MINI VARIETYCREAM 12/31/2026-5/2/2027 Helados Mexico 12-PACK DLR MINICHOCOLATE DIP VARIETY CREAM 1/14/2027-6/18/2027
Photos of the affected products are available on the FDA website.
The recall covers a wide range of "best by" dates from May 2026 through July 2027. Distribution spanned retail locations nationwide across the U.S.
As of the FDA announcement, one consumer illness has been reported. Consumers with affected items who are allergic or sensitive to milk are advised not to consume the products and to properly dispose of them.
What People Are Saying
Food Allergy Research and Education (FARE) states on its website: "When a person with a milk allergy is exposed to milk, proteins in the milk bind to specific antibodies made by the person's immune system. This triggers the person's immune defenses, leading to reaction symptoms that can be mild or very severe."
What Happens Next
Consumers who have the affected product should dispose of and not consume this product if allergic or sensitive to milk, and consult medical advice if symptoms arise.
Anyone with queries may contact the company at 909-563-3090 between 8 am and 5 pm Pacific, Monday to Friday.
The FDA will continue oversight and monitor any additional consumer reports or updates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
38 minutes ago
- Business Wire
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
BOSTON--(BUSINESS WIRE)-- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer's Disease (AD) research and treatment by offering a new approach that goes beyond symptom management. Following the recent FDA validation of organoid-based studies, the company has demonstrated a relatively rapid reduction of the Alzheimer's pathology in AD human brain organoids treated with its principal therapy; shown a significant reduction of the Tau protein, acknowledged by the Food and Drug Administration (FDA) as an AD biomarker, in other studies; and established new classes of AD therapeutics. Implementing the company's signature ' Reprogram, Restore, and Rescue ' strategy, researchers introduce healthy porosomes – neuronal secretory nanomachines – into diseased neurons to target the root causes of AD. By restoring the neuron's secretory and metabolic systems, Porosome Therapeutics' first-of-its-kind approach addresses the cellular function of AD rather than traditional symptom management. 'Unlike therapies that merely dissolve beta amyloid plaques, our platform directly targets the core biological dysfunctions of Alzheimer's, restoring both neurotransmission and metabolic integrity,' said Guillermo Marmol, CEO, Porosome Therapeutics. 'Given Alzheimer's is a serious and life-threatening disease with no effective treatment options, and based on our ability to deliver quantifiable, biomarker-driven improvements, including Tau reduction and disease reversal in human brain organoids, we are actively exploring the FDA's accelerated approval pathway.' In recent studies, the company's approach to porosome restoration has been shown to significantly reduce Tau protein levels – a key FDA-approved biomarker of Alzheimer's. The FDA's recent approval of the Tau test is a landmark development in the research for AD therapies, catalyzed by the groundbreaking science of Porosome Therapeutics. Furthermore, the company's therapeutic approach has been validated using FDA-recommended human brain organoid models, demonstrating fast clinical results with a significant reversal of Alzheimer's pathology shown within two weeks. Organoid models are three-dimensional cell cultures derived from stem cells that mimic the structure and function of human organs. 'When using human brain organoids, we're able to observe the molecular activity of the porosome at an entirely new scale,' said Bhanu P. Jena, PhD, Founder and Chairman, Porosome Therapeutics, and a distinguished cell biologist known for his discovery of the porosome nanomachine, the secretory portal of the cell. 'The ability to create an immense impact in just two weeks is a promising step forward and marks an important milestone as we advance the future of Alzheimer's research and care.' In a complementary development, the company is leveraging artificial intelligence (AI) to design proprietary decoy peptides that target and neutralize the toxic beta amyloid peptide (1-42), which is known for disrupting protein-protein interactions within the neuronal porosome complex and impairing neurotransmitter release. These specially designed AI-decoys bind more strongly to the beta amyloid (1-42), diverting the peptide from interfering with essential porosome functions. With these advances, Porosome Therapeutics has identified three distinct therapeutic classes for AD: Small Molecules and Peptides – Cross the blood-brain barrier to restore mitochondrial function. Biologics – Reconstitute the porosome complex to reverse neuronal secretory dysfunction. AI-Designed Peptides – Decoy peptides designed by AI to neutralize beta amyloid peptides (1-42) and protect neurotransmission. Porosome Therapeutics has expanded its portfolio of products to reflect these breakthroughs and the company's commitment to advancing novel treatment modalities beyond the current standard of care. About Porosome Therapeutics, Inc. Porosome Therapeutics, Inc. is a biopharmaceutical company based in Boston that leverages the groundbreaking discovery of the porosome — the cell's essential secretory machinery. The company employs innovative technologies to identify and develop proprietary therapeutics aimed at currently undruggable porosome proteins linked to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. Porosome Therapeutics is the first company to employ a technology platform dedicated to creating novel therapies targeting the porosome, recognized as the universal secretory machinery in cells. This platform is built on decades of research and is supported by over 200 published studies, proving effective against various serious diseases involving secretory defects. The platform focuses on highly specific nanobody-mediated therapies, aiming to significantly reduce drug side effects. Porosome Therapeutics' work on Alzheimer's Disease is carried out through a subsidiary, NeuroTher LLC.
Epoch Times
39 minutes ago
- Epoch Times
FDA Issues Update on Most Serious Recall for Certain Ventilators
The Food and Drug Administration (FDA) issued a notice warning that medical ventilators made by Philips Respironics are still under a Class I recall due to the potential for serious injury or death. The agency noted that the recall notice for the company's V30, A30, and A40 ventilators, which are used for obstructive sleep apnea (OSA), primarily 'involves correcting devices and does not involve removing them from where they are used or sold.'
Boston Globe
an hour ago
- Boston Globe
The FDA is targeting orange juice. Here's why, and what the science says.
Orange juice contains nutrients including calcium and Vitamin C. But some nutritionists argue that's not enough to make up for the unnecessary calories and natural sugars. 'Juices are a dilemma,' said Peter Lurie, the executive director of the nonprofit Center for Science in the Public Interest, which advocates for a healthy and safe food supply. Get Winter Soup Club A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter. Enter Email Sign Up The American Academy of Pediatrics recommends instead eating real fruit, which contains more fiber than juice. The association advises against giving fruit juice to infants except to manage constipation. It also advises limiting how much juice parents should give older children, such as no more than 4 ounces per day for kids 1 to 3 years old. Advertisement 'If you're going to have a small amount of juice, it's not going to be anything that anybody's going to worry about,' said Marion Nestle, a retired professor of nutrition, food studies and public health at New York University who called fruit juices 'delicious.' 'When you worry about juice is when it's in large amounts,' she added. Advertisement Even though leading orange juice brands do not contain added sugars, high levels of natural sugars can still be harmful, some experts said. 'Orange juice is sugar water,' said Barry Popkin, a professor of nutrition at the University of North Carolina. 'Every juice is essentially sugar water.' Once touted as part of a balanced breakfast, Americans are souring on orange juice. Consumers have gravitated toward other beverage options seen as healthier. Prices have risen. Production has stalled. And this has become a problem for Florida's orange producers. The sugar content of the fruit grown in the state has been steadily dropping due to a bacterial disease afflicting the crop, exacerbated after Hurricane Irma struck in 2017. In 2022, Florida trade groups representing the state's citrus growers and citrus juice industry petitioned the FDA to lower the minimum fruit sugar levels for pasteurized orange juice. The FDA sets a minimum standard for the sugar content in order to call a drink 'pasteurized orange juice,' the kind commonly sold at grocery stores without added sugars. If manufacturers fall below that threshold, they are essentially no longer allowed to call their products 'pasteurized orange juice." Florida orange industry groups said lowering that threshold would protect their business and reduce orange imports from other countries while going unnoticed by consumers. Sugar per serving would lower from 18 grams to 17 grams, according to nutritional label samples provided to the FDA by the industry. Other nutrients would be largely unaffected to the change. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary both pledged to examine this proposal during congressional hearings when pressed by Sen. Ashley Moody (R-Florida). Advertisement Some nutrition experts said if Kennedy wanted to advance his 'Make America Healthy Again' agenda, which included pledges to improve the diets of children, he should champion more sweeping regulations broadly targeting sugars and sodium. 'If one is serious about sugar in the American diet, we need an across the board approach,' Lurie said.
